{"product_id":"collegiumpharma-ansoff-matrix","title":"Collegium Pharmaceutical Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Collegium Pharmaceutical Ansoff Matrix Analysis shows the company’s growth options across market penetration, market development, product development, and diversification. The page already includes a real preview of the actual analysis, so you can see the content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Sales Force Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical’s commercial sales force optimization centers on a fully deployed team of 305-plus reps selling Xtampza ER, Belbuca, and Jornay PM. In Q4 2025, Jornay PM prescriptions rose 16% year over year to 200,000, showing stronger reach in high-volume prescribers. That scale supports 2026 total product revenue guidance of $805 million to $825 million before patent pressure builds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAuthorized Generic Profit Participation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Collegium Pharmaceutical leans on Hikma Pharmaceuticals’ authorized generics for Nucynta IR and Nucynta ER to soften brand erosion and keep cash flowing as prescriptions shift off the branded products. Under this model, Collegium still captures a share of net profit from generic unit sales, so the drop in revenue is slower than a normal patent cliff. That low-overhead stream helps fund its neurology franchise while reducing exposure to a full-price collapse.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFormulary Access Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium’s formulary push uses abuse-deterrent differentiation to win preferred payer status for Jornay PM and Xtampza ER. In 2025, Jornay PM kept gross-to-net in the mid-60% range, showing pricing held even as ADHD competition rose. Xtampza ER also stayed a top-5 branded ER opioid by volume, helped by payer contracts and lower nonmedical-use data versus traditional opioids.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical is using data analytics and non-personal promotion to deepen penetration in existing clinic channels. Its digital reach helped lift active prescribers to 29,000 healthcare providers as of early 2026, up 21% year over year, while tele-education and targeted outreach for Jornay PM reach busy pediatric and neurology practices without costly site visits. That lean model supports adjusted operating expense control and helps protect EBITDA margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDurable Pain Portfolio Maximization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBelbuca’s lifecycle management drove about 5% annual growth and added over $221 million to Collegium Pharmaceutical's 2025 revenue mix. Its buprenorphine base helps move long-term patients from full-agonist opioids like oxycodone, and PainConnect 2026 real-world posters reinforced the drug’s efficacy and safety, supporting durable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium's 2025 Growth: Reps, Prescribers, and Rx Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical’s market penetration strategy in 2025 is built on a 305-plus rep field force, payer wins, and targeted digital outreach, with Jornay PM prescriptions up 16% year over year to 200,000 in Q4 2025. Active prescribers reached 29,000 healthcare providers by early 2026, up 21% year over year. Belbuca added more than $221 million to 2025 revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 \/ Early 2026\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps\u003c\/td\u003e\n\u003ctd\u003e305+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJornay PM Rx growth\u003c\/td\u003e\n\u003ctd\u003e16%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive prescribers\u003c\/td\u003e\n\u003ctd\u003e29,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBelbuca revenue mix\u003c\/td\u003e\n\u003ctd\u003e$221M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nMaps out Collegium Pharmaceutical’s opportunities to grow in current and new markets with existing and new products\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Collegium Pharmaceutical Ansoff Matrix to quickly pinpoint growth gaps and simplify expansion decisions.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric ADHD Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical is pushing Jornay PM into the pediatric ADHD market by studying children ages 4 to 5 in Phase 3 trials, widening the addressable market beyond older children and teens.\u003c\/p\u003e\n\u003cp\u003eThis is a classic market development move: it aims to create earlier treatment starts and build brand loyalty at first diagnosis, which can matter in a condition that often needs long-term therapy.\u003c\/p\u003e\n\u003cp\u003eIf the trial succeeds, the younger segment could add thousands of new annual treatment starts by late fiscal 2026, but the expansion still depends on clear efficacy and safety data in this age group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Out-Licensing Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical is using geographic out-licensing to enter Canada and the European Union without paying for foreign sales infrastructure. About 95% of revenue is still domestic, so the move could turn the DETERx platform into royalty income from markets with tighter opioid controls. Analysts expect the first deal in 2026, which would mark Collegium Pharmaceutical’s first real step toward a global specialty pharma model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Neurological Payer Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium can use targeted neurological payer programs to win bulk access at large health systems that still buy mostly generics. By positioning Xtampza ER as an abuse-deterrent, system-wide safety tool, the company lowers perceived monitoring and liability risk for institutions. This market-development push is aimed at the top 100 U.S. health networks by December 2026, where even one formulary win can drive multi-site uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWorkers Compensation Channel Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's workers compensation push targets all 50 U.S. states, where insurers care most about the long tail of opioid misuse costs. Sales teams position Nucynta and Belbuca as lower-abuse, longer-use options than generic oxycodone, and TPAs help win spots on restricted drug formularies. That gives Collegium a repeat, specialty patient base that is less exposed to retail price wars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Caregiver Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical’s Direct-to-Caregiver Outreach shifts Jornay PM beyond prescribers and into parent and caregiver decision-making, where school-morning friction often drives treatment choice. By focusing on evening dosing to reduce morning transition stress, the brand fits the needs of families managing ADHD, a condition affecting about 7 million U.S. children in 2022.\u003c\/p\u003e\n\u003cp\u003eThis patient-first push can lift demand through advocacy groups, community forums, and caregiver networks, which matters in a market where nearly 1 in 10 children has an ADHD diagnosis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium Expands Jornay PM Into Younger Kids and New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical is growing Jornay PM beyond its core ADHD base by testing children ages 4 to 5 in Phase 3, aiming at earlier starts and longer use. It is also pursuing Canada and the EU through out-licensing, which would add royalty revenue without new sales staff. A caregiver-led push and health-system wins could widen access fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJornay PM pediatric expansion\u003c\/td\u003e\n\u003ctd\u003ePhase 3 ages 4 to 5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic entry\u003c\/td\u003e\n\u003ctd\u003eCanada and EU out-licensing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDemand channel\u003c\/td\u003e\n\u003ctd\u003eCaregivers and health systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eCollegium Pharmaceutical Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Collegium Pharmaceutical Ansoff Matrix analysis document you’ll receive upon purchase—no mockup, just the real file. The preview below is taken directly from the full report, so what you see here is exactly what you’ll download after checkout. Purchase unlocks the complete, professional, and detailed version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThe AZSTARYS Strategic Acquisition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn March 2026, Collegium Pharmaceutical signed a definitive agreement to acquire AZSTARYS for $650 million in cash, a move aimed at deepening its position in the multi-billion dollar ADHD market. AZSTARYS combines immediate-release and long-acting serdexmethylphenidate in one capsule, giving Collegium a complementary neuropsychiatry product that fits the product development cell of the Ansoff Matrix. Management expects the asset to add over $50 million in net revenue in the second half of 2026 alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDETERx Platform Life-Cycle Extensions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical is using DETERx, the same microsphere platform behind Xtampza ER, to build non-opioid life-cycle extensions. The design keeps release slow and steady even if a pill is crushed or cut, which helps reduce misuse risk. Management expects at least 2 early-stage candidates to enter Phase 1\/2 testing by end-2026.\u003c\/p\u003e\n\u003cp\u003eIf those programs advance, the core story shifts from pain brands to advanced drug delivery systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult Indication for Jornay PM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Jornay PM is still approved only for ADHD in patients age 6 and older, so an adult label would open direct promotion to psychiatry and internal medicine clinics. Adult ADHD is common, with U.S. prevalence estimates near 4.4%, which gives Collegium Pharmaceutical a much larger addressable pool. If trials succeed, even modest share gains could support a step-up in 2026 organic growth and lift the Jornay PM run-rate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReal-World Evidence Data Generations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium is using real-world evidence data generation to raise the perceived value of its branded pain portfolio against generics. In early 2026, it presented nine RWE posters, including at the American Academy of Pain Medicine, to show how the drugs perform in actual practice and support premium pricing talks with payers and state boards. In Ansoff terms, this is product development through evidence, turning clinical data points into marketing tools for the same product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeu neuropsychiatry Asset In-Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical uses its $980 million credit facility for neuropsychiatry asset in-licensing, targeting commercial-ready CNS drugs for insomnia and anxiety. The aim is to give its 180-member ADHD sales team more products to discuss with the same prescribers, while cutting single-asset risk and adding two assets to the 105-person pain-specialist bags by late 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium Bets $650M on AZSTARYS, Targeting H2 2026 Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical’s product development focus in 2025 centers on expanding CNS and pain assets, led by the $650 million AZSTARYS deal and its expected $50 million-plus in net revenue in H2 2026. It also keeps building DETERx-based extensions and expects at least 2 early-stage programs in Phase 1\/2 by end-2026. Jornay PM’s ADHD-only label still limits reach to the 4.4% U.S. adult ADHD pool.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2025-2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAZSTARYS acquisition\u003c\/td\u003e\n\u003ctd\u003e$650 million cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH2 2026 net revenue\u003c\/td\u003e\n\u003ctd\u003eOver $50 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly-stage programs\u003c\/td\u003e\n\u003ctd\u003eAt least 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult ADHD prevalence\u003c\/td\u003e\n\u003ctd\u003e4.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntry Into Behavioral Health Specialties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith Ironshore fully integrated and Azstarys added in 2026, Collegium moved beyond pain into CNS. \u003c\/p\u003e\n\u003cp\u003eThat shift aims to lift non-opioid products to 40% of total net revenue by 2027, reducing reliance on a tighter opioid market. \u003c\/p\u003e\n\u003cp\u003eFor investors, a broader CNS mix improves regulatory balance and lowers long-term business risk. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Digital Diagnostic Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical is testing digital monitoring apps for ADHD patients, tracking evening and morning symptoms plus medication use, so this diversification is still early and tied to select patient groups in early 2026.\u003c\/p\u003e\n\u003cp\u003eThat move pushes the company into digital therapeutics and software-as-a-service, widening its model from drug sales toward outcome tracking and patient support.\u003c\/p\u003e\n\u003cp\u003eFor a 2025-era manufacturer, the key strategic value is not near-term revenue but a higher-margin service layer that can deepen engagement and support future cross-selling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Drug Portfolio Targeted Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical’s orphan-drug M\u0026amp;A push fits a move into rare-disease CNS assets, where U.S. orphan status can deliver 7 years of exclusivity and a much higher entry bar. That would cut exposure to mass-market rebate pressure and generic copycats, and the assets would likely use a small hospital-focused sales team, not a retail rep model. Management expects a formal review in late 2026 as cash rebuilds after Azstarys.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital-Based Acute Pain Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical’s move into a hospital-based acute pain platform diversifies it from chronic pain and targets a setting where physicians want options beyond IV narcotics. By building non-opioid uses for surgical centers and emergency departments, it can reach a different US hospital revenue pool and support pre-op and post-op safety goals. The company’s acute-pain R\u0026amp;D has more than doubled over the last 24 months, showing a heavier bet on this adjacent market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Specialty Pharmacy Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical is piloting a joint venture for a closed-loop specialty pharmacy network for its controlled medicines, a clear diversification move beyond standard manufacturer operations.\u003c\/p\u003e\n\u003cp\u003eBy bypassing traditional middlemen, it could retain more gross-to-net value and gain tighter control over adherence and safety data.\u003c\/p\u003e\n\u003cp\u003eThat makes the model more integrated than direct peers and, if scaled, could reshape how Collegium manages patient fulfillment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium’s New Bets Broaden Growth, But 2025 Impact Is Still Early\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical’s diversification now spans CNS, digital monitoring, rare-disease M\u0026amp;A, and hospital acute pain, moving well beyond legacy pain. In 2025, management is still testing these bets, so near-term revenue impact is limited. The strategic value is lower concentration risk and a wider non-opioid platform.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS\u003c\/td\u003e\n\u003ctd\u003eEarly scale-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003ePilot phase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease\u003c\/td\u003e\n\u003ctd\u003eReview stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SOAR Analysis","offers":[{"title":"Default Title","offer_id":52930310078811,"sku":"collegiumpharma-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1011\/6857\/8907\/files\/collegiumpharma-ansoff-analysis.webp?v=1778314672","url":"https:\/\/soar-analysis.com\/products\/collegiumpharma-ansoff-matrix","provider":"SOAR Analysis","version":"1.0","type":"link"}